1Brown A K,Quinn M A,Karim Z,et al.Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic dug-induced clinical remission:evidence from an imaging study may explain structural progression[J].Arthritis Rheum,2006,54 (12):3761-3773.
2Van der Heijde D,Klareskog L,Landewe R,et al.Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis[J].Arthritis Rheum,2007,56(12):3928-3939.
3Tracey D,Klareskog L,Sasso E H,et al.Tumor necrosis factor antagonist mechanisms of action:a comprehensive review[J].Phannacol Ther,2008,117(2):244-279.
4Zidi I,Mcstiri S,Bartegi A,et al.TNF-alpha and its inhibitors in cancer[J].Med Oncol,2010,27(2):185-198.
5Veronese F M,Mero A.The impact of PEGylation on biological therapies[J].Bio Drugs,2008,22(5):315-329.
6Nesbitt A,Fossati G,Bergin M,et al.Mechanism of action of certolizumab pegol (CDP870):in vitro comparison with other anti-tumor necrosis factor alpha agents[J].Inflamm Bowel Dis,2007,13(11):1323-1332.
7Nesbitt A,Fossati G,Brown D.Effect of structure of conventional anti-TNF and certolizumab pegol on mode of action in rheumatoid arthritis[J].Ann Rheum Dis,2007,66(suppl II):296.
8Oussalah A,Bigard M A,Peyrin-Biroulet L.Certolizumab use in pregnancy[J].Gut,2009,58(4):608.
9Berthelot J M,De Bandt M,Goupille P,et al.Exposition to anti-TNF drugs during pregnancy:outcome of 15 cases and review of the literature[J].Joint Bone Spine,2009,76(1):28-34.
10Choy E H,Hazieman B,Smith M,el al.Efficacy of a novel PEGylated humanized anti-TNF fragment(CDP870) in patients with rheumatoid arthritis:a phase Ⅱ double-blinded,randomized,dose-escalating trial[J].Rheumatology (Oxford),2002,41(10):1133-1137.
